Twist Bioscience reported Q3 2026 revenue surpassing estimates driven by sustained demand across healthcare and industrial sectors, reflecting adoption of its high-throughput silicon chip DNA synthesis technology. Despite ongoing net losses and negative operating income, the company's integrated technology platform combining automation, proprietary software, and e-commerce enables cost advantages and rapid turnaround. Growth is supported by diversified applications spanning synthetic genes, biopharma discovery services, and NGS tools. Risks persist from dependence on single-source components, evolving customer funding cycles, and capital-intensive scale-up.